Business● LowJul 14 · Jul 14, 2026, 12:28 PM
Spero gets ex-China rights to Innovent’s antibody therapy for up to $1.1B
GlobeAlert Desk · curated from Seeking Alpha Tech
Spero has acquired ex-China rights to Innovent's antibody therapy in a deal potentially worth up to $1.1 billion. This represents a major business transaction in the biopharmaceutical sector.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
1 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business8m agoContineum Therapeutics GAAP EPS of -$0.49Seeking Alpha TechBusiness9m agoLTC reports strong Q3 earnings on SHOP acquisitions; 2026 guidance fails to impressSeeking Alpha TechBusiness9m agoInternational Flavors & Fragrances as rising costs cloud outlookSeeking Alpha TechBusiness10m agoFirst Tracks Biotherapeutics, Inc. GAAP EPS of -$0.88 beats by $0.03Seeking Alpha Tech